Drug Patent Watch
AUGUST 24, 2021
Annual Drug Patent Expirations for SYNJARDY Synjardy is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from one supplier. There are six patents…. The post New patent for Boehringer Ingelheim drug SYNJARDY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Discovery Today
AUGUST 23, 2021
Medicines Manufacturing Innovation Centre in Renfrewshire, Scotland, has topped out.
Quanticate
AUGUST 27, 2021
R is the open source software environment and language used for data analysis and statistical computing. A great deal has already been said and written about R’s wide variety of graphical and statistical techniques. Even though R as a programming language is constantly growing in popularity in the pharmaceutical industry, it is still quite unpopular to use R in the preliminary stages of research like importing data from different sources, tidying it, calculating new variables in datasets and mak
Nvidia Developer: Drug Discovery
AUGUST 24, 2021
SE(3)-Transformers are versatile graph neural networks unveiled at NeurIPS 2020. NVIDIA just released an open-source optimized implementation that uses 43x less. SE(3)-Transformers are versatile graph neural networks unveiled at NeurIPS 2020. NVIDIA just released an open-source optimized implementation that uses 43x less memory and is up to 21x faster than the baseline official implementation.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Drug Patent Watch
AUGUST 23, 2021
Annual Drug Patent Expirations for JARDIANCE Jardiance is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from four suppliers. There are six patents…. The post New patent for Boehringer Ingelheim drug JARDIANCE appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
AUGUST 22, 2021
In the early days of the COVID-19 pandemic, doctors in Wuhan noticed something surprising. Many of the elderly patients who survived the virus were poor: not exactly the demographic you would expect to fare well in a health crisis. A review of the survivors’ medical records revealed that a significant number suffered from chronic heartburn and were taking an inexpensive drug called famotidine, the key ingredient in Pepcid.
Drug Discovery Digest brings together the best content for drug research and development professionals from the widest variety of industry thought leaders.
Practical Cheminformatics
AUGUST 21, 2021
In no particular order, here's a hopefully useful, topical organization of the posts I've written over the past few years. Resources and Reviews A Highly Opinionated List of Open Source Cheminformatics Resources AI in Drug Discovery 2020 - A Highly Opinionated Literature Review Clustering Viewing Clustered Chemical Structures in a Jupyter Notebook Clustering 2.1 Million Compounds for $5 With a Little Help From Amazon & Facebook Self-Organizing Maps - 90s Fad or Useful Tool?
Drug Patent Watch
AUGUST 27, 2021
This chart shows the pharmaceutical companies with the most spray dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most spray dosed drugs…. The post Which pharmaceutical companies have the most spray dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
AUGUST 22, 2021
Positive high-level results from the PROVENT Phase III pre-exposure prophylaxis trial showed AstraZeneca’s AZD7442 achieved a statistically significant reduction in the incidence of symptomatic COVID-19, the trial’s primary endpoint.AZD7442, a combination of two long-acting antibodies (LAAB), reduced the risk of developing symptomatic COVID-19 by 77% (95% confidence interval (CI): 46, 90), compared to placebo.
Drug Patent Watch
AUGUST 22, 2021
This chart shows the drugs with the most patents in Denmark. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Denmark? appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Drug Patent Watch
AUGUST 27, 2021
Annual Drug Patent Expirations for EPCLUSA Epclusa is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are twenty-six…. The post New patent for Gilead Sciences drug EPCLUSA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2021
Annual Drug Patent Expirations for SYNJARDY+XR Synjardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are five…. The post New patent for Boehringer Ingelheim drug SYNJARDY XR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 23, 2021
This chart shows the drugs with the most patents in Switzerland. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is desired.…. The post Which pharmaceutical drugs have the most drug patents in Switzerland? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 27, 2021
Annual Drug Patent Expirations for NURTEC+ODT Nurtec Odt is a drug marketed by Biohaven Pharm and is included in one NDA. There are two patents protecting this drug. NURTEC ODT…. The post New patent for Biohaven Pharm drug NURTEC ODT appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical research has entered a new era, one that requires real-time analytics and visualization to allow trial leaders to work collaboratively and to develop, at the click of a mouse, deep insights that enable proactive study management. Learn how Revvity Signals helps drug developers deliver clinical trial data insights in real-time using a fast and flexible data and analytics platform to empower data-driven decision-making.
Drug Patent Watch
AUGUST 26, 2021
This chart shows the pharmaceutical companies with the most patents in Russian Federation. Patents must be filed in each country (or, in some cases regional patent office) where patent protection…. The post Which pharmaceutical companies have the most drug patents in Russian Federation? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 26, 2021
Annual Drug Patent Expirations for PRADAXA Pradaxa is a drug marketed by Boehringer Ingelheim and is included in two NDAs. It is available from three suppliers. There are five patents…. The post New patent for Boehringer Ingelheim drug PRADAXA appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 26, 2021
Annual Drug Patent Expirations for BYDUREON+PEN Bydureon Pen is a drug marketed by Astrazeneca Ab and is included in one NDA. It is available from one supplier. There are twenty-two…. The post New patent for Astrazeneca Ab drug BYDUREON PEN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 26, 2021
Annual Drug Patent Expirations for BYDUREON Bydureon is a drug marketed by Astrazeneca Ab and is included in two NDAs. It is available from one supplier. There are twenty-three patents…. The post New patent for Astrazeneca Ab drug BYDUREON appeared first on DrugPatentWatch - Make Better Decisions.
Advertisement
Clinical development organizations face a wide array of challenges when it comes to data, many of which can impact the operational effectiveness of their clinical trials. In this whitepaper, experts from Revvity Signals explore how solutions like TIBCO® Spotfire® enable better, more streamlined studies. The whitepaper also features a success story from Ambrx, a leading biopharmaceutical company, detailing how it has leveraged Spotfire to tackle data quality and collaboration challenges in clinic
Drug Patent Watch
AUGUST 26, 2021
Annual Drug Patent Expirations for ZYNRELEF+KIT Zynrelef Kit is a drug marketed by Heron Theraps Inc and is included in one NDA. It is available from one supplier. There are…. The post New patent for Heron Theraps drug ZYNRELEF KIT appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 25, 2021
Annual Drug Patent Expirations for IMODIUM+A-D+EZ+CHEWS Imodium A-d Ez Chews is a drug marketed by J And J Consumer Inc and is included in one NDA. There is one patent…. The post New patent expiration for J And drug IMODIUM A-D EZ CHEWS appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 25, 2021
This chart shows the drugs with the most patents in South Korea. Patents must be filed in each country (or, in some cases regional patent office) where patent protection is…. The post Which pharmaceutical drugs have the most drug patents in South Korea? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 25, 2021
Annual Drug Patent Expirations for REMODULIN Remodulin is a drug marketed by United Therap and is included in two NDAs. It is available from one supplier. There are nine patents…. The post New patent for United Therap drug REMODULIN appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2021
This chart shows the companies which have received the most GAIN Act exclusivities in the past five years. The Generating Antibiotic Incentives Now Act provides for five years of market…. The post Pharmaceutical companies with the most ‘Antibiotic GAIN Act’ drugs appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2021
Annual Drug Patent Expirations for CHILDREN%27S+ASTEPRO+ALLERGY For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com. The post New patent for Bayer Hlthcare drug CHILDREN’S ASTEPRO ALLERGY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 24, 2021
Annual Drug Patent Expirations for ASTEPRO+ALLERGY Astepro Allergy is a drug marketed by Bayer Hlthcare and is included in one NDA. The generic ingredient in ASTEPRO ALLERGY is azelastine hydrochloride.…. The post New patent for Bayer Hlthcare drug ASTEPRO ALLERGY appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 23, 2021
Annual Drug Patent Expirations for DEFITELIO Defitelio is a drug marketed by Jazz Pharms Inc and is included in one NDA. It is available from one supplier. The generic ingredient…. The post New patent for Jazz Pharms drug DEFITELIO appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 23, 2021
Annual Drug Patent Expirations for TRIJARDY+XR Trijardy Xr is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are fourteen…. The post New patent for Boehringer Ingelheim drug TRIJARDY XR appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 23, 2021
Annual Drug Patent Expirations for GLYXAMBI Glyxambi is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from one supplier. There are eleven patents…. The post New patent for Boehringer Ingelheim drug GLYXAMBI appeared first on DrugPatentWatch - Make Better Decisions.
The Pharma Data
AUGUST 22, 2021
Alexion is discontinuing CHAMPION-ALS, the global Phase III clinical trial of Ultomiris (ravulizumab) in adults with amyotrophic lateral sclerosis (ALS). This decision is based on the recommendation of the Independent Data Monitoring Committee (IDMC), following their review of data from a pre-specified interim analysis. The IDMC recommended that the trial be discontinued due to lack of efficacy.
The Pharma Data
AUGUST 22, 2021
In CheckMate -274, Opdivo nearly doubled median disease-free survival compared to placebo in the intent-to-treat population 1. Opdivo is now approved in earlier stages of disease for three types of cancer, including the first and only PD-1 inhibitor approved for urothelial carcinoma in the adjuvant setting. today announced that Opdivo ® (nivolumab) 240 mg every two weeks or 480 mg every four weeks (injection for intravenous use) was approved by the U.S.
The Pharma Data
AUGUST 22, 2021
Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today announced results from a post hoc analysis of a long-term, 3-year open-label extension (OLE) study examining efficacy and safety endpoints for the use of AUSTEDO (deutetrabenazine) tablets in younger (<55 years) and older (?55 years) patients with tardive dyskinesia (TD).
Drug Patent Watch
AUGUST 21, 2021
This chart shows the pharmaceutical companies with the most liquid dosed drugs. For a different perspective, see the most popular dosage types. The companies with the most liquid dosed drugs…. The post Which pharmaceutical companies have the most liquid dosed drugs? appeared first on DrugPatentWatch - Make Better Decisions.
Drug Patent Watch
AUGUST 21, 2021
Annual Drug Patent Expirations for ISTODAX Istodax is a drug marketed by Celgene and is included in one NDA. It is available from two suppliers. There are two patents protecting…. The post New patent expiration for Celgene drug ISTODAX appeared first on DrugPatentWatch - Make Better Decisions.
Expert insights. Personalized for you.
98 
Let's personalize your content